(RTTNews) - Shares of Guardant Health, Inc. (GH) are sliding more than 30 percent on Friday morning trade after the company reported 83 percent sensitivity for its blood-based screening test of colorectal cancer. The rivals for the company has recorded higher sensitivity and according to reports analysts were looking for higher sensitivity.
Currently, shares are at $28.83, down 30.12 percent from the previous close of $41.26 on a volume of 5,516,115.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
